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Background: The histopathological and molecular heterogeneity of normal tissue adjacent to cancerous tissue
(NTAC) and normal tissue adjacent to benign tissue (NTAB), and the availability of limited specimens make
deciphering the mechanisms of carcinogenesis challenging. Our goal was to identify histogenetic biomarkers that
could be reliably used to define a transforming fingerprint using RNA in situ hybridization.
Methods: We evaluated 15 tumor-related RNA in situ hybridization biomarkers using tumor microarray and samples
of seven tumor-adjacent normal tissues from 314 patients. Biomarkers were determined using comprehensive
statistical methods (significance of support vector machine-based artificial intelligence and area under curve scoring
of classification distribution).
Results: TP53 was found to be a most reliable index (P <10-7; area under curve >87%) for distinguishing NTAC from
NTAB, according to the results of a significance panel (BCL10, BECN1, BRCA2, FITH, PTCH11 and TP53).
Conclusions: The genetic alterations in TP53 between NTAC and NTAB may provide new insight into the field of
cancerization and tumor transformation.
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At present, tumor-adjacent tissue samples are considered
as normal specimens and normal controls in histopatho-
logical applications, and therefore often used as a stand-
ard negative control to determine whether malignant
tumors have been removed cleanly [1]. However, we can-
not guarantee that normal tissue adjacent to cancerous
tissue (NTAC) has been unaffected by the nearby malig-
nant tumor. Normal tissue adjacent to benign tissue
(NTAB) has been shown to be histologically and* Correspondence: cmtzeng@xmu.edu.cn; binxiong88@yahoo.com
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reproduction in any medium, provided the orgenetically normal, but the issue of distinguishing one
from the other in a reliable manner has continued to
elude researchers.
A growing tumor body surrounded by pathologist-
validated NTAC is by definition abnormal at the molecu-
lar level because of long-term expansion or clonal
conversion from patch to field of cancerization [1-4].
Those two models have been implicated mainly in malig-
nant tumors of the breast, skin, prostate, lung, liver, brain
and gastrointestinal tract [4-9]. However, wound-healing
does not occur in tissues adjacent to invasive cancers
[10]. The epithelial-mesenchymal transition that initiates
the invasion process of most tumors has also been
observed in NTAC [11,12]. Moreover, diverse genetic
studies of field cancerization have assessed the copy
number, expression and single nucleotide polymorphismsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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they cannot explain the mechanisms behind tumor progres-
sion, metastasis or recurrence [2,13,14]. The genetic alter-
ations between NTAC and NTAB may provide new insight
into the field of cancerization and tumor transformation.
Tumor development is a smooth process that goes
through several molecular stages, including gene transfor-
mation [15,16]. Tumor cells interact with adjacent normal
cells, indicating gene cross-talk and mutual signal transduc-
tion from the two kinds of cells [15,17-19]. Relative to be-
nign tumor cells, malignant tumor cells show more
aggressive cellular growth and integration. Thus, we could
expect that benign and malignant tumors and their adjacent
tissues would undergo different malignant transformations.
The genes that initiate tumor processes are collectively
known as tumor-related genes (TRGs) and comprise onco-
genes, tumor-suppressor genes, and genes that promote
and inhibit cancer progression and metastasis. To date,
many TRGs from malignant tumors and other cells have
been identified and intensively studied for the purposes
of explaining the molecular mechanism of cancer devel-
opment, drug discovery and diagnostics [16,20,21]. Never-
theless, few clinical studies have been specifically devoted
to the rule of TRGs in distinguishing NTAC from NTAB.
In this study, we collected tumors that were malignant
(six types) and benign (two types) and adjacent tissue
samples (eight types) from 314 patients to generate a
tumor microarray (TMA). We then used 15 histogenetic
cancer markers, or TRGs (MYC (ENSG00000136997),
CCND1 (ENSG00000110092), TP53 (ENSG00000141510),
UVRAG (ENSG00000171862), RB1 (ENSG00000139687),
PTEN (ENSG00000171862), PTCH1 (ENSG00000185920),
BRCA1 (ENSG00000012048), BRCA2 (ENSG00000139618),
FHIT (ENSG00000189283), BECN1 (ENSG00000126581),
BCL10 (ENSG 00000142867), APC (ENSG00000134982),
CD82 (ENSG00000085117) and NME1-NME2 (ENSG
00000011052)) for finding novel biomarkers involved in
cancerization or tumor transformation or recurrence
through RNA in situ hybridization (RISH) and compre-
hensive statistical analysis.
Methods
Specimen collection and tissue microarray composition
We collected 314 primary tumor biopsy samples from
Chinese patients at Zhongshan Hospital, which is affil-
iated with Xiamen University. Written informed consent
was obtained from the patients for publication of this re-
port and any accompanying images. The specimens were
collected from 2000 to 2006. Samples of normal tissue
adjacent to tumor samples were flash-frozen and stored
at −70°C before further treatment. Tumors included hepa-
tocellular carcinoma (26 cases), rectal adenocarcinoma
(48 cases), esophageal squamous cell carcinoma (34 cases),
gastric adenocarcinoma (66 cases), thyroid carcinoma(32 cases), breast carcinoma (38 cases), thyroid adenoma
(32 cases) and breast fibroadenoma (38 cases). Histologi-
cally normal tissues adjacent to tumors were selected
from the incised edges of the resected tumors. Tissue
blocks measuring approximately 1.5 × 1.5 × 0.3 cm were
fixed in PBS containing 4% paraformaldehyde (1% diethyl
pyrocarbonate, pH 7.4) for 24 hours at 4°C. Standard
treatment for paraffin sections under an RNase-free con-
trol condition was then performed. Sections stained with
hematoxylin and eosin were reviewed under microscopes
to confirm the presence of histologically normal or can-
cerous areas. Duplicated TMA chips had 1-mm-diameter
TMA cores with 0.8 mm of space between the core cen-
ters. We generated two sets of TMA of tumors (malig-
nant and benign) and para-tissue (NTAC and NTAB) for
the following RISH examination.
Preparation of tumor marker probes
Through an article search of the National Center for Bio-
technology Information PubMed database and the most
common-use RISH commercial kits (Cybrdi, Rockville,
MD, USA, we selected 15 TRGs as a starting screening
panel. Antisense probes, perfectly matched to each corre-
sponding sequence, were prepared using a ‘locked nucleic
acid’ (LNA) modification (ribose ring of the nucleotide
‘locked’ with a methylene bridge connecting the 20-O
atom with the 40-C atom) to increase stability and sensi-
tivity. Probes information is shown below:
































RNA in situ hybridization and quantification
The hybridization procedures performed in this study
were performed in accordance with the RISH kit manu-
facturer’s instructions (Cybrdi) with several modifications:
vanadyl- ribonucleoside complex (1 mM) was added to
keep RNase from causing RNA degradation, and cetyl-
trimethylammonium bromide was used to structurally
stabilize the hybridization between oligo-probes and com-
plimentary targets. LNA was used to improve the stabil-
ity and sensitivity of the monomer probes. (Detailed
protocol available upon request.) We optimized RISH with
10 ng/μL probe concentration, onto tissue microarray chip
(TMC) with regards digestion (min) and incubation (h)
time, incubation temperature (°C) and chromogenic time
(min), respectively (Table 1). Of the TRGs, MYC was
found to be 20 min / 42 h / 41.5°C / 30 min, CCND1 was
found to be 20 min / 36 h / 45°C / 50 min,TP53 was found
to be 30 min / 44 h / 48°C / 110 min,UVRAG was found to
be 30 min / 38 h / 18.5°C / 60 min, RB1 was found to be
25 min / 42 h / 21°C / 45 min, PTEN was found to be
20 min / 40 h / 19.5°C / 45 min, PTCH1 was found to
be 22 min / 40 h / 23°C / 40 min, BRCA1 was found to be
24 min / 39 h / 22°C / 40 min, BRCA2 was found to be
24 min / 39 h / 23°C / 35 min, FHIT was found to be 20
min / 44 h / 24°C / 40 min, BECN1 was found to be 24
min / 46 h / 20.5°C / 25 min, BCL10 was found to be 25
min / 40 h / 19.5°C / 90 min, APC was found to be 25 min /Table 1 Optimal conditions for RNA in situ hybridization















NME1-NME2 22 4637 h / 20°C / 80 min, CD82 was found to be 25 min / 40 h /
29°C / 35 min, and NME1-NME2 was found to be 22
min / 46 h / 20.5°C / 50 min.
RISH results were determined by measuring the ratio
of positive cells to total cells and density of staining.
The criteria for the positive cell ratio are scored as 0
for <25%, 1 for 25% to 50%, 2 for 51% to 75%, and 3
for >75%. Staining density was scored as 0 for no stain-
ing, 1 for light staining, 2 for deep staining, and 3 for
black staining. Expression levels were scored from 0 to
6 using the sums of these two scores.
Gene expression and statistical analysis
Two techniques for data analysis were implemented: a
statistical method (analyses were performed using the
SPSS 10.0 (SPSS Inc., Chicago, IL, USA) used to calcu-
late the P-values (significance <0.05) of genes in different
samples, and a support vector machine (SVM)-learning
method applied to further discover the relationship be-
tween genes and corresponding samples.
The significance levels of the 15 TRGs were analyzed
by Wilcoxon rank-sum test, which is an efficient non-
parametric statistical method to compare two groups
(NTAC and NTAB) of data and determine their differ-
ences. It is important to choose an efficient machine-
learning method to further explore the connections
between genes and different cancers. However, it is hard
to decide what kind of functions the 15 TRGs would have
for the different types of cases. So it is necessary to
separately analyze the effects of both a single gene and
different gene groups in different specimens. However,
since there are so many ways to construct a gene group
within 15 genes, efficient methods are required to shrink
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ods were used to analyze gene expression levels, includ-
ing: t test, entropy, Bhattacharyya and Wilcoxon. All
these methods were provided in a bioinformatics toolbox
embedded in MATLAB 7.1 (MathWorks, Inc., Natick,
MA, USA ). Based on different criteria for feature selec-
tion, different methods would result in genes in different
order of importance. The genes were classified into dif-
ferent groups. The discriminatory ability of the gene
groups was measured by SVM. This is a supervised
learning model with associated learning algorithm that
analyzes data and recognizes patterns, used for classifi-
cation and regression analysis. Comparing the results
revealed the genes with biological significance.
There were three steps to analyze gene expressions:
firstly, the gene expressions of different specimens were
measured with the Wilcoxon rank-sum test, so that the
P-value of each gene could be calculated, and then used
to evaluate the homological extent of the two specimens.
Secondly, the classification ability of each gene was ana-
lyzed singly among different tissues to further assess the
importance of each gene in different tissues. Thirdly, the
results obtained by the combination of different genes
were investigated. The relationship among genes could
be discovered in this way. It is easy to directly evaluate
the classification ability of a single gene using SVM with
10-fold cross-validation (CV). However, because there
are many ways to select the 15 genes to form a geneFigure 1 RNA in situ hybridization of TP53 expression for normal tissu
benign tissue. (A-D) show the NTAC from the thyroid, breast, liver and co
malignant RISH, there is no clonal patch, but there is a scattered TP53-posi
and density were visualized on a Zeiss-Axiophot DM HT microscope (Zeiss-
camera linked to a computer plus EZ-HYB software. NTAB: normal tissue ad
tissue; RISH: RNA in situ hybridization.group, it is necessary to take a reliable selection method.
In our analysis, we started with an empty gene. A filter
method was applied to rank the genes, and then a gene
was added to the group according to the score of the
rank. The gene group was used to discriminate the sam-
ples in two types of tissues using SVM by the 10-fold
CV method. This process ended when all genes were
added to the group. In addition, as the sample sizes var-
ied in different diseases, the area under the curve (AUC)
of the receiver-operating characteristic was deployed in
our experiments. A the receiver-operating characteristic
curve represents the true positive rate as a function of
the corresponding false positive rate, and the AUC pro-
vides a measure of performance that is sensitive to the
distribution of the activity classes in test sets. Using the
AUC, the problem of sample size unbalance can be solved
and the best gene subset can be determined. Lastly, the
best gene subsets can be found by the highest AUC.Results
Pathologists identified malignant and benign tumors
through immunohistocompatibility observation and by
RISH onto Formalin-Fixed Paraffin-Embedded (FFPE)
slides or TMA. From immunohistocompatibility micro-
scopic observation, we histologically confirmed eight ma-
jor carcinomas, benign tumors and associated NTAC or
NTAB tissue.e adjacent to cancerous tissue and normal tissue adjacent to
lon cancer samples, respectively. (A0-D0) show the NTAB. Unlike in
tive cell distribution, indicated by the arrow. The positive cell number
Axiophot, Oberkochen, Germany) and captured with an attached
jacent to benign tissue; NTAC: normal tissue adjacent to cancerous
Figure 2 RNA in situ hybridization expression profile of
15 tumor-related genes between normal tissue adjacent to
cancerous tissue and normal tissue adjacent to benign tissue
from 314 patients. (A) Heat map and tree map of RISH expression
for 15 TRGs. (1) and (2) NTAB in thyroid and breast tissue. (3) NTAC
for all malignant tumors. Units −3 through +3 represents the scale
of gene expression corresponding to the sample. (B) Box plot
distribution of TRG expression in (1) NTAB and (2) NTAC for 314
biopsies. NTAB: normal tissue adjacent to benign tissue; NTAC:
normal tissue adjacent to cancerous tissue; RISH: RNA in situ
hybridization; TRG: tumor-related gene.
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found that all histological RISH patterns were similar to
those discerned during prior clinical observation. The
clusters were highly dense, and there were patches of po-
sitive cells (data not shown). Most NTACs and NTABs
were arrayed on TMA. They also showed a strong distri-
bution of cells positive for 15 tumor marker probes. The
scattered distribution of probes were calculated and fur-
ther scored the gene expression level of each of the 15
genetic markers (APC, BCL10, BECN1, BRCA1, BRCA2,
FHIT, CD82, NME1, RB1, PTEN, PTCH1, UVRAG, TP53,
CCND1, MYC) by positive cell count and measurement
of staining density. Figure 1 shows the RISH of TP53 ex-
pression for NTAC and NTAB in thyroid, breast and
liver tissue, and in benign colon cancer.
No significant difference in expression was found be-
tween malignant tumors, between benign tumors, or be-
tween their related adjacent tissue. However, we did find
differences in expression between NTAC and NTAB. Ten
overexpressed and one underexpressed TRGs were iden-
tified: BECN1 with P <10-8, BCL10 with P <10-7, BRCA1
with P <10-4, BRCA2 with P <10-12, FITH with P <10-10,
CD82* with P <10-5, PTCH11 with P <10-9, PTEN with
P <10-4, TP53 with P <10-12, CyclinD1 with P <10-5, and
MYC with P <10-5.
Through analysis of the NTAC heat map, c-Myc,
CyclinD1, BRAC1, FITH, BRCA2, PTEN, TP53 and
PTCH1 were found to cause positive fold changes rela-
tive to NTAB (Figure 2A). In parallel, through analysis
of the box plot of the distribution of gene expression in
NTAC and NTAB, BRCA1, BRCA2, TP53 and CyclinD1
showed significant differences (Figure 2B). Meanwhile,
we used AUC measurement and four classical statistical
methods to filter ranking order for these 15 genes. We
used 10-fold CV runs, t-testing, entropy, Brattacharyya
distance and Wilcoxon rank-sum testing to smooth out
discrepancies between the heat map and box plot
(Figure 3).
Brattacharyya distance and entropy showed PTEN,
TP53 and RB1 to be the most significant genes, but
PTEN and RB1 showed lower AUC values, below 50%.
TP53 was found to possess over 87% AUC to be the
most reliable biomarker for distinguishing NTAC and
NTAB.
In t- and Wilcoxon rank-sum tests, TP53 was found to
be the best indicator, with an AUC value of 86%. This
implies that TP53 plays a critical role in cell transform-
ation or cancerization.
Discussion
We selected 15 TRGs known to act on various aspects
of tumor development. These included genes involved in
apoptosis (TP53, BCL10), cell-cycle control (RB1/RB,
APC, CCND1), DNA repair (BRCA1, BRCA2),autophagy regulation (UVRAG, BECN1), signaling and
enzyme activity (PTEN, PTCH1, FHIT), and metastasis
(NME1–NME2, CD82) and a single oncogene (MYC).
These genes were frequently reported as significantly dif-
ferent in expression level between selected malignant
tumors and adjacent normal tissue. However, our RISH
results showed that, between NTAC and NTAB, the
expressions of 11 of these 15 genes were significantly dif-
ferent, implying that NTAC and NTAB (baseline) share
unlikely tissues and molecular patterns, even though,
immunohistocompatibility shows them to be identical. It
can be concluded that NTAC is subject to cancer
Figure 3 The result of 15 tumor-related genes analysis. (A) AUC values from 15 tumor-related genes in normal tissue adjacent to cancerous
tissue and normal tissue adjacent to benign tissue groups. X-axis: 15 tumor-related genes; Y-axis: AUC values. (B) Results of ten runs of 10-fold CV
for gene expression in NTAB versus NTAC. Each figure represents the of one filter method. X-axis: orders of selected genes. Y-axis: average and
standard deviation of the AUC scores obtained in the ten 10-fold CV with the corresponding gene groups. AUC: area under the curve; CV: cross-
validation; NTAB: normal tissue adjacent to benign tissue; NTAC: normal tissue adjacent to cancerous tissue.
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cannot be defined as a tumor-free baseline or negative
control. Consequently, TRGs could be considered mo-
lecular indexes for monitoring the transformation of can-
cer transformation from normal tissues, which is a better
means for cancer prognosis than a histological method.
Related clonality and independent multiple lesions are
two major hypotheses of field cancerization, but they
cannot explain the genetic alterations observed in NTAC.
We found no clonal patch or loci of independent lesions
or clusters. Instead, we found a scattered distribution of
positive cells. This could be explained by inducible field
cancerization starting from the adjacent normal cells and
spreading through molecular inducers of malignancy.Recently, scientists have proposed that tumor develop-
ment involves a unique micro-environment that relies
heavily on the neighborhood fibroblasts, endothelial cells
and infiltrating fibroblasts. Inflammatory cells and im-
mune cells infiltrate into nearby non-tumor cells and
then transform the area into tumor territory [17,22].
Despite this, more than 10 TRGs were found to be sig-
nificantly expressed in NTAC compared with NTAB.
We customized the SVM-learning method to minimize
the empirical classification error and maximize the geo-
metric margin. This mainly nullified TRGs but it also
nullified TP53 from seven tumor types. In malignant tu-
mor research,TP53 is the most notable dysfunctional sup-
pressor in carcinogenesis. It behaves as a tumor marker
Liu et al. World Journal of Surgical Oncology 2012, 10:252 Page 7 of 8
http://www.wjso.com/content/10/1/252of field cancerization in breast cancer, lung cancer, brain
tumors, and skin cancer to hepatocellular carcinomas
[4,23-30]. TP53 was reported to be a valuable part of risk
assessment and a prognostic biomarker of breast cancer,
showing a high hazard ratio and statistical significance
(P < 0.0001) [26].
Conclusions
TP53 has been applied as a diagnostic biomarker either
by immunostaining or by genetic detection. We believed
that field cancerization and tumor transformation are
strongly related to NTAB or NTAC. Our finding, that
TP53 is a reliable index suitable for distinguishing NTAC
from NTAB in many clinical biopsies, is going to benefit
prognostics in malignant cancer monitoring and further
prevention
At the same time, we are working on applying genome-
wide association studies, miRNA and epigenetic methyla-
tion detection to fully decipher the molecular mechanism
of cancerization and tumor formation.
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